SPONSOR
Almirall, S.A.
Total Trials
3
Recruiting
3
Phases
Phase 2
Almirall, S.A. is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Hidradenitis Suppurativa, Atopic Dermatitis, Eczema, Plaque Psoriasis.
The trial portfolio spans Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Almirall, S.A.
How many clinical trials has Almirall, S.A. sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Almirall, S.A., of which 3 are actively recruiting participants. These trials cover conditions including Hidradenitis Suppurativa, Atopic Dermatitis, Eczema. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Almirall, S.A. research focus on?
Almirall, S.A. clinical trials span Hidradenitis Suppurativa, Atopic Dermatitis, Eczema, Plaque Psoriasis. The research pipeline includes Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Almirall, S.A. clinical trial?
To participate in a Almirall, S.A. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Almirall, S.A. trials with current recruitment status updated daily.
Clinical Trials by Almirall, S.A.
NCT07151937 Phase 2
Recruiting
A Study of LAD191 in Adults With Hidradenitis Suppurativa
Hidradenitis Suppurativa
NCT06815380
Recruiting
A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants With Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis
NCT06030076
Recruiting
A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology